RYTM · XBRL financial data

Rhythm Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RYTM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	24*	26	29	33	42*	33	49	51	57*	60	71	92
Cost of goods and services sold	3*	3	3	4	4*	4	6	5	5*	7	9	12
Research and development	30*	129	30	38	41*	37	42	46	42*	42	43	52
Selling, general and administrative	32*	34	36	35	38*	39	46	52	57*	64	67	67
Operating income (loss)	(41)*	(140)	(40)	(44)	(41)*	(47)	(45)	(53)	(47)*	(52)	(49)	(39)
Interest expense	5*	5	5	5	5*	5	6	5	5*	5	5	4
Other income (expense)	1*	1	0	1	(0)*	(1)	2	0	0*	(2)	1	(0)
Income tax expense (benefit)	0*	0	0	(0)	(0)*	0	0	0	(0)*	1	0	1
Net income (loss)	(42)*	(141)	(32)	(44)	(43)*	(49)	(47)	(53)	(48)*	(56)	(49)	(41)
Earnings per share, basic USD per share	(0.70)*	(2.35)	(0.55)	(0.73)	(0.70)*	(0.81)	(0.75)	(0.82)	(0.71)*	(0.83)	(0.73)	(0.61)
Earnings per share, diluted USD per share	(0.70)*	(2.35)	(0.55)	(0.73)	(0.70)*	(0.81)	(0.75)	(0.82)	(0.71)*	(0.83)	(0.73)	(0.61)
Weighted average shares, basic millions of shares	59*	60	61	61	62*	63	64	66	67*	68	69	69
Weighted average shares, diluted millions of shares	59*	60	61	61	62*	63	64	66	67*	68	69	69

Fiscal quarters (RYTM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	60	53	162	48	89	106	136	52	54	62	66	40
Short-term investments	216	148	157	251	231	208	155	364	335	278	265	281
Accounts receivable	15	15	18	19	19	18	26	33	26	34	40	39
Inventory	9	9	12	14	19	19	19	22	26	29	31	31
Prepaid and other current assets	9	11	9	9	16	18	25	24	26	27	25	28
Total current assets	308	236	357	340	374	369	361	495	467	430	427	419
Property and equipment, net	1	1	1	1	1	0	0	0	1	1	0	1
Right-of-use asset	1	1	4	4	3	3	3	3	3	3	3	3
Total assets	333	259	382	364	392	387	373	507	480	442	437	443
Accounts payable	5	8	5	5	12	12	16	14	14	12	16	11
Accrued liabilities	48	45	48	55	63	59	—	—	84	—	—	—
Current portion of long-term debt	—	—	—	—	2	2	4	6	7	10	13	15
Total current liabilities	55	54	55	98	116	112	129	104	106	103	124	151
Long-term debt	106	—	—	—	108	108	106	103	101	98	93	88
Lease liability, non-current	0	0	3	4	4	4	4	4	3	3	3	3
Total liabilities	163	197	202	211	228	224	239	211	210	205	220	242
Accumulated deficit	(895)	(1,036)	(1,068)	(1,112)	(1,155)	(1,205)	(1,251)	(1,304)	(1,352)	(1,408)	(1,457)	(1,498)
Total stockholders' equity	170	62	39	11	22	19	(12)	149	139	123	103	88
Total liabilities and equity	333	259	382	364	392	387	373	507	480	442	437	443
Common shares outstanding (cover page) millions of shares	60	61	61	61	63	64	66	67	68	69	69	69

Fiscal quarters (RYTM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(42)*	(141)	(32)	(44)	(43)*	(49)	(47)	(53)	(48)*	(56)	(49)	(41)
Stock-based compensation	9*	8	10*	11*	11*	13	16*	19*	19*	23	26*	25*
Depreciation and amortization	year only	—	—	—	year only	—	—	—	year only	—	—	—
Net cash from operating activities	(29)*	(41)	(29)*	(25)*	(19)*	(40)	(23)*	(27)*	(25)*	(44)	(9)*	(3)*
Purchases of property and equipment	(0)*	—	—	—	year only	—	—	—	1*	—	—	—
Net cash from investing activities	23*	30	(9)*	(91)*	21*	25	54*	(246)*	30*	57	14*	(16)*
Proceeds from issuing common stock	0*	—	—	—	year only	34	0*	0*	0*	0	0*	0*
Proceeds from long-term debt	0*	—	—	—	year only	—	—	—	year only	—	—	—
Repayments of long-term debt	3*	3	3*	3*	4*	5	4*	6*	5*	4	7*	8*
Net cash from financing activities	2*	4	146*	2*	38*	32	(1)*	189*	(3)*	(5)	(1)*	(6)*
Net change in cash	(5)*	(7)	108*	(114)*	42*	17	30*	(83)*	2*	8	3*	(25)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Dynavax Technologies	160	95	34*	117.4M	—	Q3 FY25 10-QSep 30, 2025
PERRIGO	400	1,023	83*	138.8M	—	Q2 FY26 10-QJun 27, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Ultragenyx Pharmaceutical	125	214	(97)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.